Surrozen’s (SRZN) “Buy” Rating Reiterated at HC Wainwright

Posted by George Bondi on Aug 13th, 2026

HC Wainwright restated their buy rating on shares of Surrozen (NASDAQ:SRZN – Free Report) in a research note published on Monday morning, Marketbeat reports. The firm currently has a $44.00 price objective on the stock. HC Wainwright also issued estimates for Surrozen’s Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.31) EPS, FY2027 earnings at ($5.01) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($5.47) EPS and FY2030 earnings at ($5.53) EPS.

Several other brokerages have also weighed in on SRZN. TD Cowen began coverage on Surrozen in a research report on Tuesday, April 21st. They issued a “buy” rating on the stock. Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Surrozen presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

View Our Latest Stock Report on Surrozen

Surrozen Stock Performance

Surrozen stock opened at $24.19 on Monday. Surrozen has a 1 year low of $10.06 and a 1 year high of $35.00. The firm has a 50 day moving average price of $22.90 and a 200 day moving average price of $25.53. The company has a market cap of $280.85 million, a price-to-earnings ratio of -0.60 and a beta of 0.52.

Surrozen (NASDAQ:SRZN – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.88. The company had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $0.47 million. Sell-side analysts predict that Surrozen will post -7.62 EPS for the current year.

Insider Activity

In other news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the firm’s stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $21.25, for a total value of $6,906,250.00. Following the transaction, the insider owned 574,047 shares of the company’s stock, valued at approximately $12,198,498.75. This trade represents a 36.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 31.74% of the stock is owned by insiders.

Institutional Trading of Surrozen

Several large investors have recently added to or reduced their stakes in SRZN. Geode Capital Management LLC lifted its stake in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. Armistice Capital LLC acquired a new stake in shares of Surrozen in the second quarter valued at about $536,000. Vanguard Group Inc. raised its holdings in shares of Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after buying an additional 47,468 shares during the period. Acuta Capital Partners LLC raised its holdings in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after buying an additional 8,415 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Surrozen during the 3rd quarter worth approximately $889,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.